BioFocus DPI stands to make €10.5 million, or about $15.45 million, through a deal inked with Janssen Pharmaceutica in oncology. The two-year target discovery collaboration will use an adenoviral platform from parent company, Galapagos, to identify novel drug targets.
BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation. Target discovery in in vitro assays may provide novel drug targets for cancer areas with an unmet medical need, according to the firms.
BioFocus DPI will receive an upfront payment of €2.9 million. Janssen will also pay additional research, acceptance, license, and development fees of up to €7.6 million should certain predetermined criteria be achieved.